Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Introduction

Genta, a clinical development stage biopharmaceutical company, aims to build on its core competitive strength of oncology development expertise in providing biopharmaceutical products for the treatment of cancer and to expand the pipeline of products in two therapeutic categories, DNA/RNA Medicines and Small Molecules, through internal development, licensing and acquisitions.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis

Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors

Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Genta, a biopharmaceutical company, is engaged in the identification, development, and commercialization of drugs for the treatment of cancer and related diseases in the US. The company's research portfolio consists of two programs, DNA/RNA Medicines and Small Molecules.

Genta's total revenues decreased at a CAGR of 33% during 2002-2006, from $4 million in 2002 to $1 million in 2006. The company's biggest contributor to revenue during 2002-2006 was development funding under the agreement with Aventis.

Unless Genasense receives approval, the company's only revenue source out to 2010 will be Ganite sales. Revenues from Ganite sales are expected to decrease at a CAGR of 9%, from $0.7 million in 2006 to $0.5 million in 2010, which is attributable to reduced spending and focus on the development, sale and marketing of Ganite by the company.

Reasons to Purchase

Access all the important information and analysis on the company in a single report

Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain

Gain access to company's adjusted five year financial data along with key ratios and market capitalization

TABLE OF CONTENTS
Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 9
Company Financials 12
Stock Market Performance 12
P&L 13
Balance Sheet 16
Cash Flow 16
Business Segment Performance 17
Products & Services 19
Marketed Products 19
Pipeline Products 20
Historical Product Sales 22
AC Forecast Product Sales 23
Competitors and Strategic Business Relationships 24
Key Competitors 24
Key Suppliers 24
Shareholding Structure 25
Strategy 26
Company View 26
Corporate Strategy 28
SWOT Analysis 30
Overview 30
Strengths 31
Weaknesses 32
Opportunities 33
Threats 34
Value Chain Analysis 35
Overview 35
Discovery and Product Development 35
Scorecard 37
Overview 37
Scorecard Analysis 38
Key Employees 39
List of Key Employees 39
Key Employee Biographies 40
Financial and Operational Overview 45
Financial and Operational Overview 45
APPENDIX 48
Ask the analyst 48
Datamonitor consulting 48
Disclaimer 48


TABLE OF FIGURES
Figure 1: Genta - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14
Figure 2: Genta - Key Strategic Revenues, 2002-2006 ($ Mn) 18


TABLE OF TABLES
Table 1: Genta - Key Facts 6
Table 2: Genta - Year-End Share Price and Market Capitalization, 2002-2006 ($) 12
Table 3: Genta - Key Events Impacting Share Price Performance 12
Table 4: Genta - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
Table 5: Genta - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 15
Table 6: Genta - Balance Sheet, 2002-2006 ($ Mn) 16
Table 7: Genta - Cash Flow, 2002-2006 ($ Mn) 16
Table 8: Genta - Revenue Breakdown, 2002-2006 ($ Mn) 17
Table 9: Genta - Marketed Products 19
Table 10: Genta - In-house Pipeline Products 20
Table 11: Genta - Collaboration Products 21
Table 12: Genta - Historical Product Sales, 2002-2006 ($ Mn) 22
Table 13: Genta - Forecast Sales, 2006-2010 ($ Mn) 23
Table 14: Genta – Key Suppliers 24
Table 15: Genta - Key Shareholders 25
Table 16: Genta - SWOT Analysis Summary 30
Table 17: Genta – Value Chain Analysis 35
Table 18: Genta - Scorecard 37
Table 19: Genta - Key Employees 39
Table 20: Genta - Financial and Operational Overview 46